Day: February 22, 2024

– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter and full-year ended December 31, 2023, and provided a corporate update. “2023 was a banner year for Collegium Pharmaceutical....

Montevideo, Feb. 22, 2024 (GLOBE NEWSWIRE) — MercadoLibre, Inc. Reports Fourth Quarter 2023 Financial Results MONTEVIDEO, Uruguay; February 22, 2024; (GLOBE NEWSWIRE) — MercadoLibre, Inc. (Nasdaq: MELI) (http://www.mercadolibre.com) today reported financial results for the quarter ended December 31, 2023, in a Letter to Shareholders, which is now posted to the company’s Investor Relations website https://investor.mercadolibre.com. The Company will host its earnings video conference, as well as a conference call and audio webcast for any questions that investors may have, on February 22, at 5:00 p.m. Eastern Time. To access our video webcast and the live audio, investors, analysts and the market in general may access the following link at https://edge.media-server.com/mmc/p/6vd3zgg4/ and register at the platform to attend...

GAAP EPS of $0.67 in Q4 2023 Compared with $(0.55) in Q4 2022 GAAP EPS of $3.10 in Full-Year 2023 Compared with $0.43 in Full-Year 2022 GAAP Net Income of $89.9 million in Full-Year 2023 Compared with $0.2 million in Full-Year 2022 Q4 and Full-Year Adjusted EPS* of $1.25 and $4.31 in 2023 Compared with $1.17 and $3.10 in 2022 Introducing 2024 Full-Year Adjusted EPS* Guidance Range of $4.85-$5.15 CHARLOTTE, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) — SPX Technologies, Inc. (NYSE:SPXC) (“SPX”, the “Company”, “we” or “our”) today reported results for the fourth quarter and year ended December 31, 2023. Gene Lowe, President and CEO, remarked, “I am very pleased with our full-year 2023 results, including Adjusted EBITDA* growth of 50% and Adjusted EPS* growth of 39%, which is near the top end of our guidance range. Our strong Q4 performance...

Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into second half of 2026 CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2023 financial results and corporate highlights. “We made important progress across our portfolio during 2023, advancing...

Record Revenue and Adjusted EBITDA Margin for Analytics in 2023; Q4 2023 Sees Highest Free Cash Flow with Continued Consolidated Revenue Growth; Resilient Revenue Model Poised for Sustained Growth Emphasizing Strong Cash Generation in 2024 Amid Improving Market Dynamics TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) — Altus Group Limited (ʺAltus” or “the Company”) (TSX: AIF), a leading provider of asset and fund intelligence for commercial real estate (“CRE”), announced today its financial and operating results for the fourth quarter and year ended December 31st, 2023, the approval by its Board of Directors of the payment of a cash dividend of $0.15 per common share for the first quarter ending March 31st, 2024, and its financial outlook for fiscal 2024. Unless otherwise indicated, all amounts are in Canadian dollars and percentages are...

Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease; topline data expected in second half of 2024  On track to initiate first-in-human studies of ATH-1105 for the treatment of amyotrophic lateral sclerosis in first half of 2024 Strong balance sheet to support innovative pipeline through key inflection points BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates. “We’ve made important progress in our pursuit to advance potential new treatment options for neurodegenerative...

Fourth quarter sales were $174.0 million, flat versus Q4 2022 Net income attributable to DMC was $2.8 million, while total net income was $3.6 million Adjusted net income attributable to DMC* was $5.2 million, or $0.26 per diluted share Adjusted EBITDA attributable to DMC* was $19.6 million, while total adjusted EBITDA, inclusive of non-controlling interest (NCI), was $23.3 million Free-cash flow* was $15.0 million Full-year results include record sales, adjusted EBITDA attributable to DMC, and free-cash flow performanceBROOMFIELD, Colo., Feb. 22, 2024 (GLOBE NEWSWIRE) — DMC Global Inc. (Nasdaq: BOOM) today reported financial results for its fourth quarter ended December 31, 2023. Michael Kuta, president and CEO, said, “The fourth quarter marked the end of a milestone year for DMC. In addition to reporting record sales, adjusted...

FREMONT, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) — AXT, Inc. (NasdaqGS: AXTI), a leading manufacturer of compound semiconductor substrates, today reported financial results for the fourth quarter and fiscal year, ended December 31, 2023. Management Qualitative Comments “We believe we are now beginning to see a recovery in our markets,” said Morris Young, chief executive officer. “In Q4, we achieved 18 percent sequential growth in our revenues and a 43 percent sequential improvement in our non-GAAP net income. While the overall demand environment remains somewhat soft, we are seeing increased orders for indium phosphide for both artificial intelligence (AI) and fiber optic applications. Further, the gallium arsenide market, which was the first of our markets to go into a correction, appears to have largely worked through excess...

AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) — Chuy’s Holdings, Inc. (NASDAQ:CHUY) today announced financial results for the 14 week fourth quarter and the 53 week fiscal year ended December 31, 2023. Highlights for the 14 week fourth quarter ended December 31, 2023, as compared to the 13 week fourth quarter ended December 25, 2022, were as follows:Revenue increased 11.8% to $116.3 million compared to $104.1 million in the fourth quarter of 2022. The extra operating week in fiscal 2023 contributed approximately $8.7 million in revenue. Comparable restaurant sales increased 0.3% as compared to the fourth quarter of 2022 (13 weeks vs. 13 weeks). Net income increased $3.0 million, or 121.2%, to $5.5 million, or $0.31 per diluted share, as compared to $2.5 million, or $0.14 per diluted share, in the fourth quarter of 2022. Adjusted...

SCOTTSDALE, Ariz., Feb. 22, 2024 (GLOBE NEWSWIRE) — TPI Composites, Inc. (Nasdaq: TPIC), today reported financial results for the fourth quarter and full year ended December 31, 2023. “Once again, we demonstrated our ability to navigate a challenging macro environment and finished 2023 with $161 million of unrestricted cash, resulting from a significant improvement in working capital. Throughout the year, we took advantage of the opportunity to strengthen our strategic position ahead of the wind market’s anticipated recovery and improve our liquidity,” said Bill Siwek, President and CEO of TPI Composites. “Our recently announced refinancing of Oaktree’s Series A Preferred Stock holdings provides TPI with approximately $190 million of improved liquidity through the life of the loan, permanently reduced future obligations by up to...